2026-10-13T08:50:26Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34047379 2026-10-01T17:22:58Z category_8 category_12 category_24 category_272 category_39 category_46 category_734 category_64 category_132 category_134 portal_5 item_type_1 month_year_10_2026

Antigenicity of bat sarbecoviruses using SARS-CoV-2 polyclonal convalescent sera. Nazia Thakur (9904162) Joseph Newman (5638340) Dongchun Ni (15188356) Jeffrey Seow (9415776) Abigail L. Hay (25157576) Yeonjae Lee (12256119) Ayush Upadhyay (25157573) Babatunde E. Ekundayo (25157578) John A. Hammond (7431785) Thomas P. Peacock (6536120) Kelvin Lau (1847764) Katie J. Doores (346210) Dalan Bailey (193037) Microbiology Cell Biology Evolutionary Biology Environmental Sciences not elsewhere classified Ecology Immunology Biological Sciences not elsewhere classified Cancer Infectious Diseases Virology multiple bat coronaviruses g ., rc g ., civet clade 1 viruses restricted ace2 usage mammalian ace2 proteins g ., rhgb07 using monoclonal antibodies clade 1 sarbecoviruses div >< p determined host range converting enzyme 2 2 convalescent individuals ace2 ), via using binding assays antigenicity using sera related bat sarbecoviruses using sarbecoviruses host range clade 3 pangolin ), neutralising antibodies entry assays binding domain sarbecoviruses interact sarbecoviruses exhibited rodent ace2 like rhgb07 generalist ace2 related antigenicity zoonotic potential vitally important still evidence specialist </ shifting pattern robust evidence research indicates racoon dog novel structure largely maintained including human immunodominant target human primate generalist phenotypes generalist </ especially omicron entry phenotypes diverse panel continued evolution breakthrough infections (A) Table outlining the different convalescent plasma/serum used to investigate the antigenicity of bat sarbecoviruses. These include samples from individuals following infection with the wildtype (WT), Alpha, Gamma, Delta, or Omicron BA.1 variants, either confirmed by PCR or assumed based on epidemiological data. The sample set also includes WHO International Standards provided by MRHA (NIBSC), pooled vaccinee plasma (low and high titre) and negative plasma, pooled from individuals pre-2019. Information about the COVID-19 standards and reagents can be found here: WHO/BS/2022.2427: Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern. (B) Heatmap showing the log (IC50) values of neutralisation (the dilution at which there was a 50% reduction in luciferase activity) of SARS-CoV-2, BANAL-20-52, BANAL-20-103, BANAL-20-236, Rs4231, WIV-1, RhGB07, Rc-o319 and BA.1 viruses in the presence of the MHRA (NIBSC) reference reagents. HEK293T cells stably expressing human ACE2 were used for all neutralisation assays, apart from RhGB07 and Rc-o319, where HEK293T cells overexpressing Rh. alcyone or Rh. cornutus were used, respectively (indicated by an asterisk). (C) Violin plots show collated IC50 values for the neutralisation of these viruses with each sera set, with the median, upper and lower quartiles (red lines) and limit of detection (black dotted line) shown. A one-way ANOVA with Dunnet’s multiple comparison was performed, comparing to SARS-CoV-2, with significance values indicated (* = p < 0.05, ** = p < 0.005, *** = p < 0.0005, ns = non-significant). The data underlying this Figure can be found in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003944#pbio.3003944.s017" target="_blank">S1 Data</a>. 2026-10-01T17:40:07Z Image Figure 10.1371/journal.pbio.3003944.g005 https://figshare.com/articles/figure/_p_Antigenicity_of_bat_sarbecoviruses_using_SARS-CoV-2_polyclonal_convalescent_sera_p_/34047379 CC BY 4.0